US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

40.70

-0.6300-1.52%

Post-market: 40.700.0008+0.00%16:01 EDT

Volume:3.04M

Turnover:124.86M

Market Cap:263.49B

PE:26.24

High:41.34

Open:41.32

Low:40.70

Close:41.33

Loading ...

Overview Company News Filings

Roche announces FDA approves Evrysdi tablet to treat SMA

Roche initiated with an Equal Weight at Morgan Stanley

Genentech publishes REGENCY trial data in the New England Journal of Medicine

Roche announces FDA approves Susvimo to treat DME

Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

Roche For 2025 Expects Mid-Single-Digit Sales Growth And High-Single-Digit Core EPS Growth

Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57 YoY, Sales CHF60.49B Up From CHF58.72B YoY

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

Drug Companies Raise Prices on More Than 800 Drugs in January -- Update

Genentech announces INAVO120 study met key secondary endpoint

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

Roche Expected to Report Higher Earnings, Sales -- Earnings Preview

European Pharma Companies to Report 4Q Results With U.S Policy Uncertainty in Focus -- Sector Preview

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug

Roche Holding AG Rises Wednesday, Outperforms Market

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals

Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

Roche receives FDA clearance for B-cell lymphoma diagnostic test

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":40.7,"timestamp":1746561600000,"preClose":41.33,"halted":0,"volume":3043197,"hourTrading":{"tag":"盘后","latestPrice":40.7008,"preClose":40.7,"latestTime":"16:01 EDT","volume":9482,"amount":385924.60000000003,"timestamp":1746561663728},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Closed","change":-0.63,"latestTime":"05-06 16:00:00 EDT Delay","open":41.32,"high":41.34,"low":40.7,"amount":124863074.17489992,"amplitude":0.015485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746604800000},"marketStatusCode":5,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":41.33,"volumeRatio":1.206256},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":1.206256,"shares":6474029800,"dividePrice":1.468592,"high":41.34,"amplitude":0.015485,"preClose":41.33,"low":40.7,"week52Low":30.03,"pbRate":"6.85","psRate":"3.49","week52High":44.31,"institutionHeld":0,"latestPrice":40.7,"eps":1.550894,"divideRate":0.036083,"volume":3043197,"delay":15,"ttmEps":1.550894,"open":41.32,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.66,"twentyDayClose":36,"sixtyDayClose":39.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511307914","title":"Roche announces FDA approves Evrysdi tablet to treat SMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2511307914","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511307914?lang=en_us&edition=fundamental","pubTime":"2025-02-13 00:50","pubTimestamp":1739379018,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with spin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-fda-approves-evrysdi-tablet-to-treat-sma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-fda-approves-evrysdi-tablet-to-treat-sma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2510260533","title":"Roche initiated with an Equal Weight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2510260533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510260533?lang=en_us&edition=fundamental","pubTime":"2025-02-12 17:50","pubTimestamp":1739353827,"startTime":"0","endTime":"0","summary":"Morgan Stanley initiated coverage of Roche (RHHBY) with an Equal Weight rating and CHF 305 price target The firm sees the end of Roche’s earnings d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-initiated-with-an-equal-weight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-initiated-with-an-equal-weight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1720051017.SGD","LU0106831901.USD","LU2089284900.SGD","LU0225283273.USD","LU0320765646.SGD","BK4581","LU2023251221.USD","LU0006306889.USD","BK4588","LU2111349929.HKD","BK4127","LU1989772840.SGD","LU2347655156.SGD","BK4504","IE00BZ1G4Q59.USD","LU1720051108.HKD","03165","LU1668664300.SGD","LU1732799900.SGD","LU0971096721.USD","LU2028103732.USD","LU0158827948.USD","LU0912757837.SGD","BK4585","LU1363072403.SGD","RHHBY","LU1548497426.USD","LU0795875086.SGD","LU1162221912.USD","LU0158827781.USD","LU2089283258.USD","LU0098860793.USD","LU2133065610.SGD","IE00BKVL7J92.USD","LU0314104364.USD","LU0267386448.USD","LU0795875169.SGD","LU1074936037.SGD","LU0106261372.USD","LU1989772923.USD","LU1732800096.USD","LU2357305700.SGD","BK4007","BK4534","LU2271345857.HKD","BK4516"],"gpt_icon":0},{"id":"2509713930","title":"Genentech publishes REGENCY trial data in the New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2509713930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509713930?lang=en_us&edition=fundamental","pubTime":"2025-02-07 18:15","pubTimestamp":1738923335,"startTime":"0","endTime":"0","summary":"Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus nephr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-publishes-regency-trial-data-in-the-new-england-journal-of-medicine?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-publishes-regency-trial-data-in-the-new-england-journal-of-medicine?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2509461007","title":"Roche announces FDA approves Susvimo to treat DME","url":"https://stock-news.laohu8.com/highlight/detail?id=2509461007","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509461007?lang=en_us&edition=fundamental","pubTime":"2025-02-05 00:50","pubTimestamp":1738687827,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a leading...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-fda-approves-susvimo-to-treat-dme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-fda-approves-susvimo-to-treat-dme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2508986219","title":"Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2508986219","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508986219?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:22","pubTimestamp":1738336920,"startTime":"0","endTime":"0","summary":"This week, Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity medicine, amycretin, showed superior weight loss in a study. Merck MRK announced mixed data from a phase III study on a combination regimen of its blockbuster PD-L1 inhibitor, Keytruda, in gastroesophageal cancer. The FDA granted approval for the expanded use of AstraZeneca AZN and its Japanese partner Daiichi’s antibody-drug conjugate, Enhertu, in breast cancer.Here's a recap of the week’s most important stories.Sanofi issued a fresh guidance for 2025. It expects its sales to rise by a mid-to-high single-digit percentage at CER. Sanofi also announced a 5 billion  buyback program to be executed in 2025. Sanofi expects earnings to rebound strongly in 2025 with the expectation of low double-digit percentage growth versus 4.1% in 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-sny-rhhbys-152200536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","NVO","SNY","RHHBY"],"gpt_icon":1},{"id":"2507648345","title":"Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2507648345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507648345?lang=en_us&edition=fundamental","pubTime":"2025-01-30 17:21","pubTimestamp":1738228860,"startTime":"0","endTime":"0","summary":"Roche Holding expects sales and core earnings to keep growing this year after beating analysts' expectations for 2024.The Swiss pharmaceutical giant is forecasting sales growth in the mid-single-digit range at constant exchange rates in 2025, and core earnings-per-share growth in the high-single-digit range.The company is also battling with patent losses for cancer drugs Avastin and Herceptin, lung-disease treatment Esbriet, rheumatoid-arthritis treatment Actemra and eye drug Lucentis. Schinecker said Roche is expecting a hit of around 1.2 billion Swiss francs  in biosimilars in line with last year, which he said was \"very much digestible.\". Sales rose 3% last year to 60.50 billion Swiss francs. Adjusting for currency movements, sales were up 7%, with growth in both its pharmaceuticals and diagnostics divisions at constant currencies. Analysts had forecast sales of 60.41 billion Swiss francs, according to consensus estimates by Visible Alpha.Core earnings per share--Roche's preferred m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2507126186","title":"Roche For 2025 Expects Mid-Single-Digit Sales Growth And High-Single-Digit Core EPS Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2507126186","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507126186?lang=en_us&edition=fundamental","pubTime":"2025-01-30 16:05","pubTimestamp":1738224325,"startTime":"0","endTime":"0","summary":"For 2025, the company expects mid-single-digit sales growth and high-single-digit core EPS growth, with a further increase in dividends in Swiss francs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43328476/roche-for-2025-expects-mid-single-digit-sales-growth-and-high-single-digit-core-eps-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHVF","RHHBF","RHHBY"],"gpt_icon":0},{"id":"2507612310","title":"Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57 YoY, Sales CHF60.49B Up From CHF58.72B YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2507612310","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507612310?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:59","pubTimestamp":1738223974,"startTime":"0","endTime":"0","summary":"Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57 YoY, Sales CHF60.49B Up From CHF58.72B YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/43328416/roches-q4-adj-eps-chf18-80-up-from-chf18-57-yoy-sales-chf60-49b-up-from-chf58-72b-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche's Q4 Adj. EPS CHF18.80 Up From CHF18.57 YoY, Sales CHF60.49B Up From CHF58.72B YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHVF","RHHBY","RHHBF"],"gpt_icon":0},{"id":"2507353612","title":"Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2507353612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507353612?lang=en_us&edition=fundamental","pubTime":"2025-01-30 15:56","pubTimestamp":1738223760,"startTime":"0","endTime":"0","summary":"0756 GMT - Roche delivered solid results in line with expectations but its diagnostics' profitability disappoints, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's core EBIT of its diagnostics unit missed Vontobel's estimates by 10.5% which surprises as only 1Q was still affected by the pandemic washout, the analyst says. Its 2025 guidance is conservative, unchanged under the new management, he adds. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2507528354","title":"Drug Companies Raise Prices on More Than 800 Drugs in January -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2507528354","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507528354?lang=en_us&edition=fundamental","pubTime":"2025-01-29 04:00","pubTimestamp":1738094400,"startTime":"0","endTime":"0","summary":"Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a median 4% at the start of this year.The modest size of the annual increases could help companies avoid criticism of gouging from President Trump while seeking his administration's support for such priorities as taking aim at the rebates given to middlemen and altering a federal program providing discounts to certain hospitals. Last year's median price increase was 4.5%.Prices rose on brand-name medicines sold by companies ranging from Pfizer to Novartis and Bristol-Myers Squibb, according to an analysis for The Wall Street Journal by 46brooklyn, a nonprofit drug-pricing research group.Although most companies kept increases below 10%, some drugs were already so expensive that even relatively moderate boosts can add hundreds or even thousands of dollars to the monthly tab.\"People really can't tell whether Trump and the administration are going to move forward with lo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","LU1804176565.USD","PFE","AMGN","LU1718418525.SGD","LU1894683264.USD","LU1066051498.USD","SGXZ31699556.SGD","BMY","LU2242652126.USD","LU1623119135.USD","LU1720051108.HKD","LU0354030438.USD","IE00BSNM7G36.USD","LU2360106947.USD","LU0061475181.USD","03165","NVS","LU1868836757.USD","SG9999018865.SGD","LU0306806265.USD","LU1917777945.USD","IE00BK4W5L77.USD","LU2237443622.USD","IE00BJT1NW94.SGD","BK4592","BK4578","LU2361045086.USD","REGN","LU0868494617.USD","LU1868836914.USD","LU2112291526.USD","SG9999003800.SGD","BK4585","LU1267930730.SGD","LU0943347566.SGD","LU1571399168.USD","LLY","LU2237443978.SGD","LU1093756168.USD","LU0456855351.SGD","LU0385154629.USD","LU1720051017.SGD","SG9999001440.SGD","LU2357305700.SGD","LU1261432733.SGD","SG9999001176.SGD","SGXZ57979304.SGD","IE00B19Z3581.USD","RHHBY"],"gpt_icon":1},{"id":"2506359952","title":"Genentech announces INAVO120 study met key secondary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2506359952","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506359952?lang=en_us&edition=fundamental","pubTime":"2025-01-28 18:30","pubTimestamp":1738060212,"startTime":"0","endTime":"0","summary":"Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study investigating It...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-announces-inavo120-study-met-key-secondary-endpoint?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-announces-inavo120-study-met-key-secondary-endpoint?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2506561775","title":"Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2506561775","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506561775?lang=en_us&edition=fundamental","pubTime":"2025-01-28 15:24","pubTimestamp":1738049040,"startTime":"0","endTime":"0","summary":"0723 GMT - A late-stage trial showed that Roche's advanced breast cancer drug Itovebi not only delays disease progression but that these patients also live longer, Vontobel analyst Stefan Schneider says in a note. \"Itovebi was already approved for first-line therapy on its primary endpoint last October and today's secondary endpoint reinforces that today,\" the analyst says. Vontobel leaves unchanged its 1.5 billion Swiss francs peak sales estimate for the drug in 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2506378059","title":"Roche Expected to Report Higher Earnings, Sales -- Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2506378059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506378059?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:21","pubTimestamp":1737976860,"startTime":"0","endTime":"0","summary":"Roche Holding is scheduled to report results for 2024 on Thursday. Here is what to know.--R&D productivity: Roche's longer-term R&D spend growth is in focus among investors as doubts around its R&D productivity, due to high-profile trial failures in recent years, persist, according to Jefferies. Roche said it would keep its 2025 R&D spend roughly flat in the short term. While many of its 2025 readouts are considered high risk, positive results could help rebuild confidence, Jefferies said.--Pipeline: Investors will keep an eye on Roche's multiple sclerosis treatment Ocrevus that is expected to post high-single-digit growth, Jefferies analysts said. Trends of eye drug Vabysmo will also draw attention amid Roche's pipeline revamp, after the European Medicines Agency granted approval for the switch to a pre-filled syringe form, Jefferies said.--FX headwinds: The company's full-year sales, profit and guidance for 2025 should be broadly in line with consensus estimates, Jefferies said. Roch","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2506264443","title":"European Pharma Companies to Report 4Q Results With U.S Policy Uncertainty in Focus -- Sector Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2506264443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506264443?lang=en_us&edition=fundamental","pubTime":"2025-01-27 17:00","pubTimestamp":1737968400,"startTime":"0","endTime":"0","summary":"European pharmaceutical companies start to report results for the fourth quarter this week. Analysts anticipate that remarks from executives on pipeline progress and the new U.S. administration, which could review vaccine mandates, will be the recurring themes when companies report earnings for the last quarter of 2024. Here is what you need to know>. Pharma stocks have underperformed the market in the fourth quarter with the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--down 9.4% against a 2.2% fall for the broader Stoxx Europe 600 index over the same period. Chinese market volatility and the new U.S. administration have negatively weighed on selected share prices, especially those with vaccines exposure, Berenberg analysts say.--  Analysts and investors will look at what guidance the major EU pharma companies will set for 2025 as all of them expect key results for potential blockbuster drugs toward the second half of the year","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNY","LU1093756325.SGD","LU0154236417.USD","03165","IE00BFTCPJ56.SGD","LU1829250122.USD","LU0109394709.USD","BK4568","BK4532","LU2236285917.USD","LU2462157665.USD","AZN","IE00BKVL7J92.USD","IE00BFXG1179.USD","LU2456880835.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","MKKGY","NVO","BK4578","LU0889565916.HKD","BK4007","LU0320765992.SGD","BK4588","NVS","IE0002141913.USD","BAYRY","GSK","LU0211331839.USD","LU1093756168.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU2417539215.USD","BK4585","IE00BZ1G4Q59.USD","BK4599","IE0009355771.USD","GSK.UK","RHHBY"],"gpt_icon":1},{"id":"2505885711","title":"FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2505885711","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505885711?lang=en_us&edition=fundamental","pubTime":"2025-01-24 19:28","pubTimestamp":1737718080,"startTime":"0","endTime":"0","summary":"Biogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of its blockbuster spinal muscular atrophy  drug Spinraza.This new proposed dosing regimen simplifies administration by offering two initial 50 mg doses spaced 14 days apart, followed by a 28 mg maintenance dose every four months. This approach reduces the dosing frequency compared to the current regimen, which requires four loading doses of 12mg administered at an interval of 14 days, followed by a 12 mg maintenance dose every four months.Biogen’s regulatory filings are supported by data from the phase II/III DEVOTE study, which achieved its primary endpoint of statistically significant improvement in motor function in infants with SMA treated with a higher dose of Spinraza.Per management, a higher dose regimen of the drug has the potential to slow neurodegeneration faster through greater reductions in neurofilament as early as day 64 relative to the currently appr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-ema-accept-biogens-filings-112800166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","BK4585","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BIIB","IE00B19Z9P08.USD","BK4588","BK4532","NVS","LU0109394709.USD","IE0002141913.USD","03165","BK4533","IE00BFTCPJ56.SGD","LU0320765992.SGD","RHHBY","BK4007","IONS","IE00BJJMRZ35.SGD","IE00B19Z9Z06.USD","IE0009355771.USD","LU0211331839.USD","IE00B894F039.SGD","BK4139","BK4578","IE00BJT1NW94.SGD","LU0234570918.USD"],"gpt_icon":0},{"id":"2505775216","title":"Roche Holding AG Rises Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2505775216","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505775216?lang=en_us&edition=fundamental","pubTime":"2025-01-23 01:17","pubTimestamp":1737566220,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 1.3% to CHF273.80 Wednesday on what proved to be an overall favorable trading session for the stock market, with the Swiss SMI Index  rising 0.8% to 12,207.89.This was the stock's third consecutive day of gains.Roche Holding AG closed CHF14.40 below its 52-week high of CHF288.20, which the company achieved on September 2, 2024.Trading volume was 1,185,850, compared to the 50-day average trading volume of 1,062,637.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2503613438","title":"Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2503613438","media":"Dow Jones","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503613438?lang=en_us&edition=fundamental","pubTime":"2025-01-15 18:22","pubTimestamp":1736936520,"startTime":"0","endTime":"0","summary":"1022 GMT - Swiss companies are expected to have distributed a record level of dividends in 2024 as share buybacks declined, Vontobel analysts say in a research note. Total dividends by companies in the Swiss Performance Index are estimated to have exceeded 60 billion Swiss francs last year, a 1.2% increase from 2023, according to Vontobel. Contract drug manufacturer Siegfried and real-estate company PSP Swiss Property are set to join Vontobel's list of \"dividend aristocrats\" that have increased payouts for at least 10 consecutive years, the analysts say. Roche, Nestle and Novartis currently top the list, having boosted their dividends for the past 37, 29 and 27 years, respectively. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4588","IE00B4R5TH58.HKD","BK4007","NVS","RHHBY","03165","IE0009355771.USD","IE00BJT1NW94.SGD","LU0211331839.USD","IE00BJJMRZ35.SGD","BK4585","IE0002141913.USD","NSRGY","BK4578","BK4532","IE00B2B36J28.USD","BK4212"],"gpt_icon":0},{"id":"2503539538","title":"ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2503539538","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503539538?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:18","pubTimestamp":1736785080,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its approved products Onpattro , Amvuttra , Givlaari  and Oxlumo .The company also issued its net product revenue guidance for 2025 and outlined several key products and pipeline updates for the year.Both Onpattro and Amvuttra are approved for the treatment of polyneuropathy of hereditary transthyretin-mediated  amyloidosis.Givlaari is approved for the treatment of acute hepatic porphyria. Oxlumo is approved for treating primary hyperoxaluria type 1  to lower urinary oxalate levels in pediatric and adult patients.Amvuttra, Givlaari and Oxlumo have witnessed strong patient demand so far, while Onpattro sales are declining as more patients are switching to treatment with Amvuttra.In the past year, shares of Alnylam have rallied 23.1% against the industry’s decline of 16%.Total Onpattro and Amvuttra net product revenues are expected to be in the range of $1.60-$1.72 billio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alny-announces-preliminary-2024-results-161800919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2362540622.SGD","LU0882574055.USD","PBYI","LU2237438978.USD","BK4139","BK4585","LU0053666078.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","REGN","RHHBY","BK4548","LU0114720955.EUR","LU2468319806.SGD","LU0289739699.SGD","LU2023250504.SGD","ALNY","LU0823416689.USD","LU2362541513.USD","BK4007","LU1974910355.USD","LU2089984988.USD","LU0058720904.USD","LU0889565916.HKD","LU1917777945.USD","03165","LU2362541273.HKD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2503589293","title":"Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589293","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503589293?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:22","pubTimestamp":1736774520,"startTime":"0","endTime":"0","summary":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ sentiment.Eylea’s Sales Decline Hampers REGN Ophthalmology Unit. Lead drug Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. Eylea sales have boosted the company’s top line for many years. However, Eylea’s sales have been under pressure in the last couple of years due to competition from Roche’s RHHBY Vabysmo.To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it now seems Eylea HD will take some time to offset the rapid erosion in Eylea sales.The company also has other arrows in its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-stock-plunges-35-6-132200313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REGN","SNY","BK4139","LU2362541273.HKD","LU1974910355.USD","LU0823416689.USD","IE0002141913.USD","LU2023250504.SGD","LU2089984988.USD","LU2362541513.USD","BK4121","LU1057294990.SGD","LU0882574055.USD","BK4566","LU0053666078.USD","CRL","LU0889565916.HKD","BK4581","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","03165","BK4534","LU1917777945.USD","LU0868494617.USD","LU1571399168.USD","BK4533","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2106854487.HKD","LU0058720904.USD","BK4530","FL","BK4585","IE00BFTCPJ56.SGD","RHHBY","SG9999001440.SGD","LU0390134368.USD","LU2242646821.SGD","IE0009355771.USD","BAYRY","IE00BFXG1179.USD","LU2237438978.USD","LU1983299246.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4007","LU0114720955.EUR","LU1061106388.HKD","AMGN"],"gpt_icon":0},{"id":"2503743963","title":"Roche receives FDA clearance for B-cell lymphoma diagnostic test","url":"https://stock-news.laohu8.com/highlight/detail?id=2503743963","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503743963?lang=en_us&edition=fundamental","pubTime":"2025-01-13 18:50","pubTimestamp":1736765434,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received 510(k) clearance from the FDA for its highly-sensitive in-situ hybridisation test, the Ventana Kappa a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-clearance-for-b-cell-lymphoma-diagnostic-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-fda-clearance-for-b-cell-lymphoma-diagnostic-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","03165"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":127,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1745899200000}}}